These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35059867)

  • 1. The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials.
    Ojo AS; Ojukwu SG; Asemota J; Akinyemi O; Araoye MO; Saleh M; Ali A; Sarma R
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):897-911. PubMed ID: 35059867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials.
    Ojo AS; Akinyemi O; Araoye MO; Ali A
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e27-e40. PubMed ID: 36402701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
    Lonial S; Jacobus S; Fonseca R; Weiss M; Kumar S; Orlowski RZ; Kaufman JL; Yacoub AM; Buadi FK; O'Brien T; Matous JV; Anderson DM; Emmons RV; Mahindra A; Wagner LI; Dhodapkar MV; Rajkumar SV
    J Clin Oncol; 2020 Apr; 38(11):1126-1137. PubMed ID: 31652094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
    Rajkumar SV; Bergsagel PL; Kumar S
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):293-303. PubMed ID: 38158241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study.
    Mateos MV; Hernández MT; Salvador C; Rubia J; de Arriba F; López-Corral L; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Bladé J; Lahuerta JJ; San-Miguel J
    Eur J Cancer; 2022 Oct; 174():243-250. PubMed ID: 36067617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
    Kunacheewa C; Manasanch EE
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical approach to the management of smoldering myeloma.
    Joseph NS; Lonial S
    Curr Opin Oncol; 2020 Nov; 32(6):656-663. PubMed ID: 32890022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Advances in the Management of Smoldering Myeloma.
    Khan R; Zahid U; Kollu V; Jahan N; Ali M; Tricot G; Anwer F
    Am J Ther; 2020; 27(2):e194-e203. PubMed ID: 31842112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding high-risk smoldering multiple myeloma.
    Kreiniz N; Gertz MA
    Leuk Lymphoma; 2023; 64(8):1361-1372. PubMed ID: 37229535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Early Intervention in High-Risk Smoldering Myeloma.
    Joseph NS; Dhodapkar MV; Lonial S
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-9. PubMed ID: 32182141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact.
    Kunacheewa C; Manasanch EE
    Expert Rev Hematol; 2021 Dec; 14(12):1059-1069. PubMed ID: 34550841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoldering Multiple Myeloma: To Treat or Not to Treat.
    Kapoor P; Rajkumar SV
    Cancer J; 2019; 25(1):65-71. PubMed ID: 30694862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies.
    Zhao AL; Shen KN; Wang JN; Huo LQ; Li J; Cao XX
    Cancer Manag Res; 2019; 11():5599-5611. PubMed ID: 31296995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing treatment for smoldering myeloma: is earlier better?
    Hernández JÁ; Martínez-López J; Lahuerta JJ
    Expert Rev Hematol; 2019 May; 12(5):345-354. PubMed ID: 30907176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
    Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
    Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.
    Nooka AK; Wang ML; Yee AJ; Kaufman JL; Bae J; Peterkin D; Richardson PG; Raje NS
    JAMA Oncol; 2018 Dec; 4(12):e183267. PubMed ID: 30128502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. State of the science in smoldering myeloma: Should we be treating in the clinic?
    Hill E; Dew A; Kazandjian D
    Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.
    van Beurden-Tan CHY; Franken MG; Blommestein HM; Uyl-de Groot CA; Sonneveld P
    J Clin Oncol; 2017 Apr; 35(12):1312-1319. PubMed ID: 28240968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.